Medicamen OrganicsNSE:MEDIORG -2.81%21 EBITDA Margin % is -149.79% as of Mar. 2026. GuruFocus rates NSE:MEDIORG with a GF Score™ of 21/100. The stock has 11 warning signs investors should review. Among 953 Drug Manufacturers companies, Medicamen Organics ranks worse than 93.49% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Medicamen Organics's EBITDA for the
six
months ended in Mar. 2026 was ₹-71.57 Mil. Medicamen Organics's Revenue for the
six
months ended in Mar. 2026 was ₹47.78 Mil. Therefore, Medicamen Organics's EBITDA margin for the quarter that ended in Mar. 2026 was -149.79%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Medicamen Organics EBITDA Margin % Related Terms
Medicamen Organics EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Medicamen Organics's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:MEDIORG vs ZTS, UTHR: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Medicamen Organics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medicamen Organics EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Medicamen Organics's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Medicamen Organics's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medicamen Organics (NSE:MEDIORG) has a EBITDA Margin % of -149.79% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Medicamen Organics and its competitors. According to the industry distribution chart, Medicamen Organics ranks #891 out of 953 companies in the Drug Manufacturers industry, placing it in the top 93.5%.
Is Medicamen Organics' EBITDA Margin % too high?
Medicamen Organics' current EBITDA Margin % is -149.79%. Based on the distribution chart, Medicamen Organics ranks #891 out of 953 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Medicamen Organics has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Medicamen Organics' EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Medicamen Organics ranks #891 out of 953 companies for EBITDA Margin %. This places Medicamen Organics in the lower half of its industry. The industry median EBITDA Margin % is 12.54. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.54, based on 953 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Medicamen Organics and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medicamen Organics's current EBITDA Margin % is -149.79%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medicamen Organics stock overvalued right now?
Medicamen Organics (NSE:MEDIORG) has a current EBITDA Margin % of -149.79%. The current EBITDA Margin % is -149.79%. Medicamen Organics' overall GF Score™ is 21/100 with 11 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Medicamen Organics (NSE:MEDIORG), the current EBITDA Margin % is -149.79% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Medicamen Organics Ltd develops, manufactures, and distributes a wide range of pharmaceutical dosage forms, including Tablets, Capsules, Oral Liquids, Ointments, Gel, Syrups, Suspension and Dry powders. The company operates two WHO Good Manufacturing Practice certified facilities in India, producing products for both domestic and international clients. It provides contract manufacturing and loan license services to various pharmaceutical companies and exports to several countries across Africa, CIS, and South Asia. The principal source of revenue is through the manufacturing, export, and contract services focused on generic and branded pharmaceutical formulations.
21GF Score
Get the complete analysis for NSE:MEDIORG
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:MEDIORG has been successfully added to your 